The discovery and clinical development of RPR 106541: An airway-selective steroid for the treatment of asthma

Expert Opinion on Emerging Drugs

Volumn 5, Issue 2, 2000, Pages 231-239

  Warne, P J ^a  

^a Aventis Pharma Ltd   (United Kingdom)

Author keywords

asthma; drug development strategy; glucocorticoid; inflammation; RPR10541; surrogate markers

Indexed keywords

ANTIASTHMATIC AGENT; BUDESONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; RPR 106541; SALBUTAMOL; STEROID; TRIAMCINOLONE ACETONIDE; TYROSINE AMINOTRANSFERASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TOLERANCE; ENZYME INDUCTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; REVIEW; SIDE EFFECT; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0033919242     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.5.2.231     Document Type: Review

References (7)

1. HANSEN R: Biomolecular Research and Development-Pharmaceutical Product Development In The Changing Healthcare Environment. In: Medical and Healthcare Marketplace Guide (1999):I-169
2. CUSHING: The basophil adenomas of the pituitary body and their clinical manifestations. Bull. John Hopkins Hosp. (1932) 50:137.
3. KELLEY HW: Comparison of inhaled corticosteroids. Ann. Pharmacother. (1998) 32(2):220-232
4. SORKNESS CA: Establishing a therapeutic index for the inhaled corticosteroids: part II. Comparisons of systemic activity and safety among different inhaled corticosteroids. J. Allergy Clin. Immunol. (1998) 102:S52-64.
5. JOHNSON M: Development of fluticasone propionate and comparison with other inhaled corticosteroids. J. Allergy Clin. Immunol. (1998) 101:S434-439.
6. ROHDEWALD PJ: Comparison of clinical efficacy of inhaled glucocorticoids. Arzneimittelforschung (1998) 48:789-796. (Pubitemid 28394104)
7. JARVIS B, FAULDS D: Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages (Pubitemid 29231893)